Anzeige
Mehr »
Freitag, 22.08.2025 - Börsentäglich über 12.000 News
Übernahme-Kracher: Diese Übernahme eröffnet völlig neue Wachstumschancen im Krypto-Sektor
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
163 Leser
Artikel bewerten:
(1)

Epigenetics Market is expected to generate a revenue of USD 3.70 Billion by 2031, Globally, at 13.94% CAGR: Verified Market Research

The global Epigenetics Market is experiencing rapid growth driven by rising demand for precision medicine, growing cancer research, and increasing applications in drug discovery. However, challenges such as high costs of advanced technologies, lack of skilled professionals, and limited awareness in emerging economies restrain widespread adoption, creating both opportunities and barriers for industry players.

LEWES, Del., Aug. 22, 2025 /PRNewswire/ -- The Global Epigenetics Market Size is projected to grow at a CAGR of 13.94% from 2024 to 2031, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 1.30 Billion in 2024 and is expected to reach USD 3.70 Billion by the end of the forecast period.

Verified Market Research Logo

The Epigenetics Market is witnessing strong expansion as research in oncology, neurology, and personalized medicine surges. With breakthroughs in biomarkers and diagnostics, epigenetic tools are reshaping drug development, though cost and expertise remain key challenges to mainstream adoption.

For a detailed analysis of industry trends and growth drivers, explore the full Epigenetics Market.

Browse in-depth TOC
202 - Pages
126 - Tables
37 - Figures

Global Epigenetics Market Overview

Market Driver

1. Rising Demand for Precision Medicine

The Epigenetics Market is being propelled by the rapid adoption of precision medicine. As healthcare systems shift toward personalized treatment strategies, epigenetic tools are proving vital in delivering targeted solutions.

  • Precision medicine relies on biomarkers for disease-specific insights, and epigenetics provides accurate molecular-level data.
  • Applications in oncology, neurology, and cardiovascular diseases are fueling demand for advanced epigenetic platforms.
  • Pharmaceutical and biotechnology firms are channeling heavy investments into epigenetic research to enhance personalized therapies.
  • Growing awareness among clinicians and patients regarding the benefits of tailored treatments is driving adoption globally.

2. Advancements in Cancer Research and Diagnostics

Cancer research continues to be a key driver supporting Epigenetics Market expansion. Epigenetic biomarkers are now integral to early detection, disease monitoring, and therapeutic optimization.

  • Technologies like DNA methylation and histone modification are enabling breakthroughs in oncology diagnostics.
  • Rising global cancer incidence is pushing research institutions and healthcare providers to adopt advanced epigenetic tools.
  • Increased funding for cancer research in both public and private sectors is boosting epigenetics adoption.
  • Integration of epigenetics into clinical workflows is reshaping cancer treatment outcomes and advancing precision oncology.

3. Expanding Role in Drug Discovery and Development

Epigenetics is emerging as a powerful tool for accelerating pharmaceutical research and drug development. By offering deeper insights into gene regulation, it is reshaping therapeutic pipelines.

  • Epigenetics enables identification of novel drug targets, improving efficiency in drug discovery.
  • It reduces development timelines by providing predictive data on drug efficacy and toxicity.
  • Pharmaceutical companies are utilizing epigenetic platforms to create therapies for autoimmune, neurodegenerative, and rare genetic disorders.
  • The push for innovation in drug pipelines, combined with growing healthcare investments, is ensuring global adoption.

Market Restraints

1. High Cost of Epigenetic Technologies

One of the biggest barriers to Epigenetics Market growth is the significant cost burden associated with advanced technologies.

  • High investment is required for next-generation sequencing platforms, reagents, and computational analysis tools.
  • Smaller biotech companies and research institutions in resource-constrained economies face difficulties in adoption.
  • Limited funding opportunities in developing regions further restrict commercialization of epigenetic products.
  • The capital-intensive nature of these technologies slows down large-scale integration in clinical practice.

2. Shortage of Skilled Professionals and Technical Expertise

Epigenetics is a specialized field requiring advanced molecular biology, genomics, and bioinformatics expertise. The lack of skilled professionals is a critical restraint.

  • Research laboratories often face difficulties in managing complex experimental setups and data interpretation.
  • There is a shortage of structured training programs focusing on epigenetic research and applications.
  • Academic institutions in emerging regions have not fully integrated epigenetics into their core life sciences curricula.
  • This talent gap delays market expansion and slows down innovation in epigenetic-based diagnostics and therapeutics.

3. Limited Awareness in Emerging Economies

While developed markets like North America and Europe lead adoption, awareness in developing regions remains significantly low.

  • Healthcare providers and policymakers in Asia-Pacific, Latin America, and Africa often lack exposure to epigenetics applications.
  • Low awareness results in underutilization of advanced technologies despite their potential in improving healthcare outcomes.
  • Limited government support and absence of national-level initiatives restrain the growth of epigenetic adoption.
  • Lack of industry-academic collaborations in these regions further slows knowledge transfer and adoption rates.

Download a free sample to access exclusive insights, data charts, and forecasts from the Epigenetics Market Sample Report.

Geographical Dominance: North America dominates the Epigenetics Market, driven by advanced healthcare infrastructure, strong R&D funding, and early adoption of precision medicine. The U.S. leads with extensive cancer research programs and pharmaceutical investments, while Canada supports growth through genomics initiatives. Europe follows closely with Germany, U.K., and France leveraging biotech innovation. Meanwhile, Asia-Pacific, led by China, Japan, and India, is emerging rapidly due to growing healthcare investments, expanding clinical research, and rising demand for epigenetic-based diagnostics.

Key Players

The "Global Epigenetics Market" study report will provide a valuable insight with an emphasis on the global market. The major players in the market are Thermo Fisher Scientific, Inc., Illumina, Inc., Merck KGaA, QIAGEN N.V., Bio-Rad Laboratories, Inc., Abcam plc., Zymo Research Corp., New England Biolabs, Inc., Active Motif, Inc., Promega Corporation, F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Revvity, Inc.

Epigenetics Market Segment Analysis

Based on the research, Verified Market Research has segmented the global market into Product Type, Application, End-User, and Geography.

  • Epigenetics Market, by Product Type
    • Kits and Reagents
    • Instruments and Equipment
    • Enzymes
  • Epigenetics Market, by Application
    • Oncology
    • Neurology
    • Developmental Biology
  • Epigenetics Market, by End-User
    • Academic Research
    • Pharmaceutical and Biotechnology Companies
    • Clinical Laboratories
    • Government Research Institutes
  • Epigenetics Market, by Geography
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • U.K.
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • Rest of Asia Pacific
    • ROW
      • Middle East & Africa
      • Latin America

Strategic Insight:

The Epigenetics Market presents strong growth opportunities, fueled by rising precision medicine demand, advancements in cancer research, and expanding drug discovery applications. However, high costs, limited expertise, and low awareness in emerging economies pose challenges. North America remains the dominant hub, supported by advanced infrastructure and funding, while Asia-Pacific offers untapped potential with increasing healthcare investments. For market entry, companies should focus on cost-effective innovations, partnerships with research institutions, and awareness-building initiatives to unlock long-term growth across developed and emerging regions.

To gain complete access with corporate or enterprise licensing, visit the Epigenetics Market.

Key Highlights of the Report:

  • Market Size & Forecast: In-depth analysis of current value and future projections
  • Segment Analysis: Breaks down the market by Product Type, Application, End-User for focused strategy development
  • Regional Insights: Comprehensive coverage of North America, Europe, Asia-Pacific, and more
  • Competitive Landscape: Profiles key players, their strategic initiatives, and innovation-driven growth approaches
  • Growth Drivers & Challenges: Analyzes the forces accelerating growth and the restraints hindering large-scale adoption
  • Challenges and Risk Assessment: Evaluates ethical debates, off-target effects, and regulatory complexities

Why This Report Matters:

This report provides a deep dive into market trends, opportunities, and challenges shaping the future of epigenetics. It equips businesses, researchers, and investors with actionable insights to make informed decisions and capitalize on emerging opportunities in healthcare innovation.

Who You Should Read This Report:

  • Market research professionals analyzing healthcare trends
  • Pharmaceutical and biotechnology companies
  • Investors seeking growth opportunities in life sciences
  • Academic and research institutions
  • Healthcare policymakers and consultants

Browse Related Reports:

Global CGT Drugs Market Size By Therapy Type (Cell Therapy, Gene Therapy, Gene-Modified Cell Therapy), By Application (Oncology, Genetic Disorders, Rare Diseases, Ophthalmology), By End-user (Hospitals, Cancer Care Centers, Pharmaceutical and Biotechnology Companies), By Geography, And Forecast

Global De Novo Sequencing Market Size By Technology (Next-Generation Sequencing (NGS), Sanger Sequencing, Third-Generation Sequencing (TGS)), By Application (Whole Genome Sequencing, Targeted Sequencing, Transcriptome Sequencing, Metagenomics, Epigenetics), By End-User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Clinical Laboratories, Contract Research Organizations (CROs)), By Geography, And Forecast

Global Cell And Gene Therapy Bioassay Services Market Size By Type of Therapy (Cell Therapy, Gene Therapy), By Test Type (Functional Assays, Cell Proliferation Assays, Cytokine Analysis), By Therapeutic Area (Oncological Disorders, Genetic Disorders, Infectious Diseases), By Geography, And Forecast

Global Optogenetics Market Size By Product Type (Light Instruments, Sensors, Actuators), By Application (Cardiology, Retinal Disease Treatment, Neuroscience), By Technique (Transgenic Animals, Viral Transduction, Cre-Dependent Expression), By Geography, And Forecast

Top 7 Regenerative Medicine Companies shaping future of care and healing

Visualize Epigenetics Market using Verified Market Intelligence -:

Verified Market Intelligence is our BI Enabled Platform for narrative storytelling in this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us

Verified Market Research® stands at the forefront as a global leader in Research and Consulting, offering unparalleled analytical research solutions that empower organizations with the insights needed for critical business decisions. Celebrating 10+ years of service, VMR has been instrumental in providing founders and companies with precise, up-to-date research data.

With a team of 500+ Analysts and subject matter experts, VMR leverages internationally recognized research methodologies for data collection and analyses, covering over 15,000 high impact and niche markets. This robust team ensures data integrity and offers insights that are both informative and actionable, tailored to the strategic needs of businesses across various industries.

VMR's domain expertise is recognized across 14 key industries, including Semiconductor & Electronics, Healthcare & Pharmaceuticals, Energy, Technology, Automobiles, Defense, Mining, Manufacturing, Retail, and Agriculture & Food. In-depth market analysis covers over 52 countries, with advanced data collection methods and sophisticated research techniques being utilized. This approach allows for actionable insights to be furnished by seasoned analysts, equipping clients with the essential knowledge necessary for critical revenue decisions across these varied and vital industries.

Verified Market Research® is also a member of ESOMAR, an organization renowned for setting the benchmark in ethical and professional standards in market research. This affiliation highlights VMR's dedication to conducting research with integrity and reliability, ensuring that the insights offered are not only valuable but also ethically sourced and respected worldwide.

Follow Us On: LinkedIn | Twitter | Threads | Instagram | Facebook

Contact Us
Mr. Edwyne Fernandes
Verified Market Research®
US: +1 (650)-781-4080
US Toll Free: +1 (800)-782-1768
Email: sales@verifiedmarketresearch.com
Web: https://www.verifiedmarketresearch.com/

Logo: https://mma.prnewswire.com/media/2015407/VMR_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/epigenetics-market-is-expected-to-generate-a-revenue-of-usd-3-70-billion-by-2031--globally-at-13-94-cagr-verified-market-research-302536681.html

© 2025 PR Newswire
Tech-Aktien mit Crash-Tendenzen
Künstliche Intelligenz, Magnificent Seven, Tech-Euphorie – seit Monaten scheint an der Börse nur eine Richtung zu existieren: nach oben. Doch hinter den Rekordkursen lauert eine gefährliche Wahrheit. Die Bewertungen vieler Tech-Schwergewichte haben historische Extremniveaus erreicht. Shiller-KGV bei 39, Buffett-Indikator auf Allzeithoch – schon in der Dotcom-Ära war der Markt kaum teurer.

Hinzu kommen euphorische Anlegerstimmung, IPO-Hypes ohne Substanz, kreditfinanzierte Wertpapierkäufe in Rekordhöhe und charttechnische Warnsignale, die Erinnerungen an 2000 und 2021 wecken. Gleichzeitig drücken geopolitische Risiken, Trumps aggressive Zollpolitik und saisonale Börsenschwäche auf die Perspektiven.

Die Gefahr: Aus der schleichenden Korrektur könnte ein rasanter Crash werden – und der könnte vor allem überbewertete KI- und Chipwerte hart treffen.

In unserem kostenlosen Spezial-Report zeigen wir Ihnen, welche Tech-Aktien am stärksten gefährdet sind und wie Sie Ihr Depot vor dem Platzen der Blase schützen könnten.

Holen Sie sich den neuesten Report!

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.